Curcumin inhibits transforming growth factor-β activity via inhibition of smad signaling in HK-2 cells

American Journal of Nephrology

Volumn 31, Issue 4, 2010, Pages 332-341

  Hu, Ying ^a   Liang, Hua ^a   Du, Yong ^a   Zhu, Yongliang ^a   Wang, Xuanding ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Curcumin; Fibrosis; HK 2 cells; Microcystin; Smad; TGF 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CURCUMIN; MICROCYSTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR REGULATED SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL GROWTH; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CELLS, CULTURED; CURCUMIN; HUMANS; KIDNEY TUBULES, PROXIMAL; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 76549101674     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000287230     Document Type: Article

References (45)

1. Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
2. Ruiz-Torres MP, Lopez-Ongil S, Griera M, Diez-Marques ML, Rodriguez-Puyol M, Rod riguez-Puyol D: The accumulation of extracellular matrix in the kidney: consequences on cellular function. J Nephrol 2005; 18: 334-340.
3. Ban CR, Twigg SM: Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 2008; 4: 575-596.
4. Okon K: Tubulo-interstitial changes in glomerulopathy. II. Prognostic significance. Pol J Pathol 2003; 54: 163-169.
5. Burns WC, Kantharidis P, Thomas MC: The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs 2007; 185: 222-231.
6. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG: Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995; 130: 393-405.
7. Miyazono K: TGF signaling by Smad proteins. Cytokine Growth Factor Rev 2000; 11: 15-22.
8. Mauviel A: Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol Med 2005; 117: 69-80.
9. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y: The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999; 56: 104-132.
10. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP: Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000; 58: 1841-1850.
11. Hocevar BA, Howe PH: Analysis of TGF-beta- mediated synthesis of extracellular matrix components. Methods Mol Biol 2000; 142: 55-65.
12. Heldin C, Miyazono K, ten Dijke P: TGF signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471.
13. Wang W, Koka V, Lan HY: Transforming growth factor-beta and Smad signaling in kidney diseases. Nephrology (Carlton) 2005; 10: 48-56.
14. Ammon HP, Wahl MA: Pharmacology of Curcuma longa . Planta Med 1991; 57: 1-7.
15. Kuttan G, Kumar KB, Guruvayoorappan C, Kuttan R: Antitumor, anti-invasion, and antimetastatic effects of curcumin. Adv Exp Med Biol 2007; 595: 173-184.
16. Kunnumakkara AB, Anand P, Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
17. Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M: Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 2008; 76: 1340-1351.
18. Surh YJ, Chun KS: Cancer chemopreventive effects of curcumin. Adv Exp Med Biol 2007; 595: 149-172.
19. Lopez-Lazaro M: Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 2008; 52(suppl 1):S103-S127.
20. Menon VP, Sudheer AR: Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 2007; 595: 105-125.
21. Calabrese V, Bates TE, Mancuso C, Cornelius C, Ventimiglia B, Cambria MT, Di Renzo L, De Lorenzo A, Dinkova-Kostova AT: Curcumin and the cellular stress response in free radical-related diseases. Mol Nutr Food Res 2008; 52: 1062-1073.
22. Lin JK: Suppression of protein kinase C and nuclear oncogene expression as possible action mechanisms of cancer chemoprevention by curcumin. Arch Pharm Res 2004; 27: 683-692.
23. Madden K, Flowers L, Salani R, Horowitz I, Logan S, Kowalski K, Xie J, Mohammed SI: Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer. Prostaglandins Leukot Essent Fatty Acids 2009; 80: 9-18.
24. Aggarwal BB, Sung B: Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009; 30: 85-94.
25. Punithavathi D, Venkatesan N, Babu M: Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol 2000; 131: 169-172.
26. Gaedeke J, Noble NA, Border WA: Curcumin blocks multiple sites of the TGF signaling cascade in renal cells. Kidney Int 2004; 66: 112-120.
27. Sharma S, Kulkarni SK, Chopra S: Curcumin, the active principle of turmeric (Curcuma longa) , ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006; 33: 940-945.
28. Bayrak O, Uz E, Bayrak R, Turgut F, Atmaca AF, Sahin S, Yildirim ME, Kaya A, Climentepe E, Akcay A: Curcumin protects against ischemia/reperfusion injury in rat kidneys. World J Urol 2008; 26: 285-291.
29. Kuwabara N, Tamada S, Iwai T, Teramoto K, Kaneda N, Yukimura T, Nakatani T, Miura K: Attenuation of renal fibrosis by curcumin in rat obstructive nephropathy. Urology 2006; 67: 440-446.
30. Ghosh SS, Massey HD, Krieg R, Fazelbhoy ZA, Ghosh S, Sica DA, Fakhry I, Gehr TW: Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation. Am J Physiol Renal Physiol 2009; 296:F1146-F1157.
31. Gesualdo L, Ranieri E, Monno R, Rossiello MR, Colucci M, Semeraro N, Grandaliano G, Schena FP, Ursi M, Cerullo G: Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kindey Int 1999; 56: 461-470.
32. Chomczynski P, Sacchi N: The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 2006; 1: 581-585.
33. Schnaper HW, Jandeska S, Runyan CE, Hubchak SC, Basu RK, Curley JF, Smith RD, Hayashida T: TGF-beta signal transduction in chronic kidney disease. Front Biosci 2009; 14: 2448-2465.
34. Peirce MJ, Munday MR, Peachell PT: Characterization of protein serine/threonine phosphatase activities in human lung mast cells and basophils. Br J Pharmacol 1998; 125: 1095-1101.
35. Ventura JJ, Nebreda AR: Protein kinases and phosphatases as therapeutic targets in cancer. Clin Transl Oncol 2006; 8: 153-160.
36. Youhua Liu: Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
37. Yang J, Liu Y: Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465-1475.
38. Liu FY, Li XZ, Peng YM, Liu H, Liu YH: Arkadia regulates TGF-beta signaling during renal tubular epithelial to mesenchymal cell transition. Kidney Int 2008; 73: 588-594.
39. Kortlever RM, Nijwening JH, Bernards R: Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity. J Biol Chem 2008; 283: 24308-24313.
40. Ma LJ, Fogo AB: PAI-1 and kidney fibrosis. Front Biosci 2009; 14: 2028-2041.
41. Brown KA, Pietenpol JA, Moses HL: A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 2007; 101: 9-33.
42. Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner AM: Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor beta actions in hepatocytes - but without modulating bone morphogenetic protein 7 signaling. Hepatology 2009; 49: 2021-2030.
43. Honkanen RE, Zwiller J, Moore RE, Daily SL, Khatra BS, Dukelow M, Boynton AL: Characterization of microcystin-LR, a potent inhibitor of type 1 and type 2A protein phosphatases. J Biol Chem 1990; 265: 19401-19404.
44. Evers R, Chu XY: Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity. Mol Pharmacol 2008; 74: 309-311.
45. Lu H, Choudhuri S, Ogura K, Csanaky IL, Lei X, Cheng X, Song PZ, Klaassen CD: Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. Toxicol Sci 2008; 103: 35-45.